STERIS plc (STE) Earnings Call Transcript & Summary

August 6, 2026

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 29 min

What were the key takeaways from STERIS plc's August 6, 2026 earnings call?

In the first quarter of fiscal year 2027, STERIS plc reported total revenue growth of 7%, with adjusted earnings per diluted share of $2.59, reflecting an 11% increase year-over-year. Management maintained its guidance for fiscal 2027, projecting revenue growth of 7% to 8% and earnings per share between $11.10 and $11.30. Notably, the company announced a significant $600 million investment in a new formulated chemistry center in North Carolina, which is expected to enhance long-term growth and profitability.

What topics did STERIS plc cover?

  • Revenue Growth: Total as reported revenue grew 7% in the first quarter, driven by a combination of volume and pricing. Management stated, "Constant currency organic revenue grew 6% in the quarter, driven by volume as well as 190 basis points of price."
  • Margin Expansion: Gross margin improved to 46%, up 70 basis points year-over-year, attributed to pricing and productivity gains. Karen Burton noted, "Margin expansion was driven by price and favorable productivity, which were somewhat offset by inflation."
  • Investment in North Carolina: Management announced a $600 million investment to build a new formulated chemistry center, the largest investment in a single manufacturing site in company history. Dan Carestio emphasized, "This investment strengthens our health care and life sciences formulated chemistries business, which together generate more than $700 million in revenue."
  • Free Cash Flow Decline: Free cash flow for the quarter was $279.6 million, down from $326.5 million in the prior year. Karen Burton explained that the decline was "driven primarily by a lower contribution from working capital, despite improvement in net income."
  • Healthcare Segment Performance: Healthcare segment revenue grew 6%, with service revenue up 10%. Carestio stated, "Our service team continued its streak of outperformance, growing 10% in the first quarter."

What were STERIS plc's August 6, 2026 results?

  • Adjusted EPS: $2.59 (+11% YoY)
  • Gross Margin: 46% (+70 basis points YoY)
  • EBIT Margin: 23.8% (+100 basis points YoY)
  • Free Cash Flow: $279.6M
  • Capital Expenditures: $87.5M
  • Total Debt: $1.9B

Overall, STERIS plc's first quarter results indicate strong revenue growth and margin expansion, supported by strategic investments. However, the decline in free cash flow and challenges in the AST segment raise concerns. Investors should monitor the execution of the North Carolina investment and the recovery trajectory in the AST segment as potential catalysts for future performance.

Earnings Call Speaker Segments

Julie Winter

executive
#1

Thanks, Nick. Morning, everybody. On the line today we'll hear from our CFO, Karen Burton — she's a Senior Vice President — along with Dan Carestio, who serves as our President and CEO. Ahead of the remarks, I want to share a brief note of caution. The information in this webcast is time-sensitive, meaning it holds true only as of today. Redistributing, retransmitting, or rebroadcasting this call is strictly forbidden unless STERIS has given its express written consent. Certain statements shared during this review are, or could be viewed as, forward-looking. Actual results might wind up differing materially from what those forward-looking statements suggest, owing to a number of significant factors — among them, and not limited to, the risk factors laid out in STERIS' securities filings. STERIS isn't committing to refresh or amend any forward-looking statements because of fresh data, upcoming occurrences, or later changes. You can get the company's SEC filings from STERIS itself or through our site. Also, during this call, we'll reference non-GAAP financial metrics such as adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth, and free cash flow. Definitions for these metrics and other details appear in our release, along with the reconciliations comparing GAAP and non-GAAP financial measures. During this call, we're sharing non-GAAP financial measures because we want to give you more visibility into the extra financial details that management and the Board of Directors rely on when they analyze finances and make operational decisions. With those notes in place, I'll turn things over to Karen.

Karen Burton

executive
#2

Thanks, Julie. Morning, everyone. I'm glad to be here today to walk through what stood out in our first-quarter results. In Q1, revenue on a total as-reported basis rose 7%. Organic revenue in constant currency was up 6% for the quarter, with volume plus 190 basis points of price fueling that. Our gross margin came in at 46% for the quarter, which is 70 basis points higher than a year ago. That margin gain came from price and good productivity, partly offset by inflation. Gross tariff costs before refunds totaled $14 million in Q1. Keep in mind, tariffs last year in the first quarter were $12 million. We got $4 million of tariff refunds during the quarter; comparing year over year, net tariffs came in $2 million favorable. To be clear, we aren't allocating tariff refunds into our business segments — they go into corporate instead, which lets us analyze the segments. EBIT margin was 23.8% of revenue for the quarter, 100 basis points above the first quarter a year ago. Better gross margin, along with helpful currency and disciplined operating costs, produced that EBIT margin gain in the quarter. Our adjusted effective tax rate was 25.9% in the quarter, versus 23.5% in last year's first quarter. That year-over-year rise came mainly from unfavorable discrete items. Adjusted net income was $253.4 million for the quarter. Diluted earnings per share reached $2.59, up 11% from a year earlier. Stronger margins outweighed the higher tax expense. Capital expenditures were $87.5 million in the quarter, while depreciation and amortization came to $123.8 million; we closed the quarter with a solid balance sheet, showing $1.9 billion of total debt. At quarter end, gross debt to EBITDA stood at roughly 1.1x, comfortably under our 2x to 2.5x targets. Free cash flow was $279.6 million for the quarter, lower than the $326.5 million we posted in last year's first quarter. That drop in free cash came mostly from a smaller working capital contribution, even though net income improved. We spent $100 million on share buybacks in Q1, which leaves $900 million remaining under our current authorization; last week we also declared our 21st straight year of dividend increases, raising it by $0.06 to $0.69 each quarter, as dividend growth remains a priority for us. With that, I'll hand things over to Dan for his comments.

Dan Carestio

executive
#3

Appreciate that, Karen. Morning, everybody. Thanks for being here as we discuss how we did in the first quarter of 2027 and what we expect for the rest of the year. Karen already walked through the quarter at a high level. I'll offer a few additional remarks about our segments. Beginning with Healthcare, organic revenue in constant currency was up 6% during Q1. Results showed steady demand underneath, and our commercial organizations keep generating significant growth throughout the Healthcare segment. Our portfolio's strength keeps allowing us to assist customers in steering through a complicated operating landscape. Our service team extended its run of strong results, posting 10% growth in Q1. Consumables were up 9%, helped by greater customer usage, which came from share gains and procedure growth in endoscopy. Revenue from Healthcare capital equipment rose 1% in the quarter, with shipment timing weighing on that growth. Orders stayed healthy, rising 4% in Q1, and our ending backlog climbed to $444 million. EBIT margins for Healthcare during the quarter were up 60 basis points, reaching 24.8%, as volume, pricing, positive productivity, and favorable mix were partly offset by inflation, business investments, and tariffs. Now for AST, organic revenue in constant currency rose 5% in the quarter, including 6% growth in services. As we expected given tough comparisons, services volume was soft during the quarter. Worldwide demand is still somewhat weak as customers keep working down inventory they already hold. EBIT margins for AST came in at 48%, down 60 basis points versus the first quarter a year ago, since extra pricing was more than outweighed by higher depreciation and marginally weaker productivity. Organic revenue in constant currency for the Life Sciences group climbed 8% in the quarter. Driving that increase, capital equipment was up 17% and consumables rose 8%. Services were up 2%. Backlog when the quarter closed was roughly level with the prior year at $110 million. Margins reached 42.1%, down 140 basis points, as pricing and volume were more than offset by unfavorable productivity and inflation. Before we move on to the outlook, I'd like to address yesterday's announcement that we're putting $600 million into a new Formulated Chemistry Center of Excellence in North Carolina. As our release mentioned, this represents the biggest investment in a single manufacturing site in our company's history. We'll construct two facilities with 600,000 sq ft under roof in total, covering manufacturing, R&D, and distribution. The site will make high-performance infection prevention and contamination control chemistries that our healthcare and pharmaceutical customers around the world use. This investment bolsters our healthcare and life sciences formulated chemistries business, which combined brings in over $700 million in revenue. These products are high growth, high margin, and highly regulated; they're essential in helping our customers achieve safe, compliant outcomes for patients. This investment puts us in position to scale alongside our customers, backs rising demand, and maintains growth in these strategically important portfolios over the long term. We anticipate that this site will start operating within two to three years, rolling out in stages, with distribution kicking things off first. Once it's finished, our plan is to move operations over from the chemistry manufacturing and distribution locations we have in St. Louis, Missouri, and Plymouth, Minnesota, and then shut those sites down. With the Formulated Chemistry Center of Excellence fully in place, we'll be able to speed up innovation, add more capacity, and make our U.S. chemistries manufacturing and distribution network more efficient. Because of this, we made an announcement today about a restructuring program, and we expect pretax restructuring charges somewhere around $55 million-$70 million, which breaks down into roughly $40 million-$50 million in cash expenditures plus about $15 million-$20 million in non-cash charges. Our expectation is that under $10 million of that will hit fiscal 2027; this investment should deliver an ROIC above 10% within three to five years after opening, and it's critical for our growth and profitability over the long term. Turning now to the outlook. Taking into account our first quarter results and what we expect for the rest of the year, we're keeping our original outlook for fiscal 2027 in place. That means as-reported revenue growth of 7%-8% along with constant currency organic revenue growth of 6%-7% for the whole company. Our fiscal 2027 earnings per share outlook stays the same too, at $11.10-$11.30, which represents growth of 9%-11% over fiscal 2026. The total cost of the North Carolina facility is projected to reach $600 million, but the effect on fiscal 2027 should be roughly $75 million in extra capital spending. Consequently, CapEx is now projected at about $450 million for fiscal 2027. Free cash flow is now anticipated to come in at $800 million, since the strong first quarter performance is helping offset the extra CapEx spend this year; for modeling purposes, the North Carolina investment will be spread across the next three years. At this point, we expect the project to contribute approximately $350 million in capital spending in fiscal 2028, with the remaining $175 million falling in fiscal 2029. This project is still in its early stages of development, and we'll share more updates on timing once things become clearer. I want to thank all of our associates for continuing to do what we do best, keeping our focus on customers and working to do a little better each day. Thank you. That wraps up our prepared remarks for the call. Operator, could you please provide the instructions so we can get the Q&A started?

Brett Fishbin

analyst
#4

Morning, everyone. I really appreciate you letting me ask a few things. Nice progress reported today. I'd like to dig a bit into what's happening beneath the surface with AST service. You've mentioned before that growth would build as the year went on, since the first half faced hard comps and inventory effects. So I'm wondering how you're viewing growth going forward, and whether you still see a step up in 2H.

Dan Carestio

executive
#5

Thanks, Brett. Dan here. As you noted, the first half of last year had difficult comps. We think that will persist for a while longer. Comparisons get easier once destocking began showing up in Q3. At that stage, we'd expect the growth rates for AST to pick up speed. The fundamentals haven't shifted at all. Starting last year at 13% across the first six months has held growth back somewhat at present.

Brett Fishbin

analyst
#6

All right, that's good. If I could just dig into the other segment that came in somewhat softer during this quarter, which is healthcare capital equipment. You did bring up timing, and the backlog figure still appeared quite robust. Perhaps you could give us a bit more context regarding what happened with the timing of orders and placements, and also how you expect that to build up.

Dan Carestio

executive
#7

Yeah. Our backlog grew, as you can see, and it's truly only a matter of timing. We saw a 4% increase in orders; at this moment we're gaining genuine momentum in the marketplace. I have very strong confidence that across the fiscal year, our capital equipment business will deliver healthy growth; the payoff from 18 months of strong capital sales is now coming to us through the pull-through we're seeing in our consumables and chemistry, consumable chemistry, sterility assurance, and services.

Brett Fishbin

analyst
#8

Okay, that wraps up my questions. I believe I picked up on a remark you made regarding market share improvement in endoscopy. If you wouldn't mind elaborating just a bit, which areas of the portfolio are generating those gains? Thanks very much.

Dan Carestio

executive
#9

Sure. Allow me to restate that, or make it clearer: what we've observed is stronger expansion in endoscopy when it comes to procedure volume growth. Roughly one-third of our healthcare franchise ties back to endoscopy, and that's working in our favor. We are indeed taking share there, I can tell you that with confidence, on the equipment side through the automatic endoscope reprocessors, which are fueling healthy growth for our chemistries — our dedicated chemistries — plus the services tied to repairing endoscopes and various instruments.

Brett Fishbin

analyst
#10

Okay, thanks so much.

Dan Carestio

executive
#11

Yeah.

Patrick Wood

analyst
#12

Great. Thanks, everyone. Two questions from me, if you don't mind. First, I'm probably too dense to fully grasp all this tariff business, but let's say we removed both the refund you actually received and the related expense — really pretending it never happened. Would the underlying margins, stripping all of that out, have gone up? And if yes, what's the reason? That's my first one. Then very quickly, my second: the $600 million deployment, that's clearly a major step for you. What was it — you brought up efficiencies and distribution outside — but it's a big move, so what actually tipped things toward moving all of that production? Thanks.

Karen Burton

executive
#13

Thanks, Patrick. I'll handle the first one. I'd also be happy to avoid discussing tariffs. The gross margin is up. Without tariffs, we saw favorability from price and productivity. The tariff refunds did help offset some of that cost. It's included in the gross margin. Our actual tariff costs came to $14 million in the quarter, and I don't think I'd remove those. They aren't going anywhere.

Dan Carestio

executive
#14

Dan here, Patrick — I appreciate the question. Regarding what we're doing with chemistry capacity expansion: think back to the time we bought Cantel. Cantel brought a sizable chemistry production site located in Minnesota, while our own sizable site sits in St. Louis, Missouri. The trouble is that expansion isn't truly possible at either one, and down the road both will be pushing right up against their maximum capacity. So if we wanted to make any move at all, a greenfield build was the only path. After reaching that conclusion, and with consolidation coming soon, we began figuring out where to put it, and given how well distribution works and the pool of skilled people available — particularly in STEM fields — we settled on North Carolina. For us, this plant is going to represent the facility of tomorrow. Automation will be a major feature; it will have the appearance and atmosphere of a pharma clean room. It's going to be quite something to see.

Patrick Wood

analyst
#15

That's great. Thank you, everyone.

Mac Etoch

analyst
#16

Good morning, and I appreciate you fielding my questions. Some worries have come up regarding how much hospitals are being used and the number of procedures being performed. Your healthcare consumables business posted quite impressive expansion. I would really like to dig deeper into how that segment performed and what you are observing in that end market. Thanks.

Dan Carestio

executive
#17

Thank you, Mac. Dan here. We have not observed any deceleration at all, and we are seeing robust expansion, particularly within the ASC sector; specifically, as I noted earlier, in endoscopy, which matters a great deal to STERIS when it comes to the effect on our procedure growth. I recognize, and we are deeply engaged in discussions with our clients regarding the difficult conditions they operate in now and will operate in going forward when it comes to payment. We do not anticipate any near-term or long-term consequence where procedures are concerned. Consequently, we remain confident about our customers' ability to endure over the long haul.

Mac Etoch

analyst
#18

Thanks for that. I'm curious to understand what you're observing in life sciences. Reshoring has come up in conversation, yet it remains something that hasn't fully arrived, and I'd really like to hear what you're picking up regarding possible projects that are in the pipeline.

Dan Carestio

executive
#19

That's a fascinating point. When reshoring comes up, it isn't simply about relocating to the U.S. Localization is taking place all over the world as tariffs play a bigger role in Europe and in the U.S. You're going to notice certain manufacturing sites being duplicated, while previously, there might have been a single facility worldwide dedicated to one pharmaceutical product. That works in our favor, since it generates demand for expanding or augmenting the manufacturing footprint, which typically calls for the tools, sterilizers, washers, and similar equipment, to be brought into those aseptic manufacturing environments. Plus it provides us with additional at-bats and chances to get our chemistries installed into the cleaning processes; this is occurring. It isn't a revolution, but whenever manufacturing experiences disruption or change, generally, that represents a solid opportunity for us.

Mac Etoch

analyst
#20

I appreciate the color.

Dan Carestio

executive
#21

Sure thing.

Jason Bednar

analyst
#22

Morning, and thanks for fielding these. Dan, I'd like to revisit AST. You brought up inventory destocking. Does the pace of volume growth line up with what you planned for this year? Drawing on what you've heard from customers, could you describe the level of visibility you have into that segment picking up from where it sits today and the destocking problem not lingering?

Dan Carestio

executive
#23

Yes. It went into our model, so our expectation was that it would last through Q2, followed by an AST ramp-up during the back half of the year. Largely, that is what we're seeing, and we'd anticipate it carrying on, with gains beginning to show — my hope is by the close of the second quarter, and certainly meaningful gains in performance by Q3.

Jason Bednar

analyst
#24

Alright, that's great. Karen, I've got a couple of follow-ups for you. Just so we're all clear, the total refund you've gotten so far is only $4 million. Every bit of that went to corporate, and it gives gross margins a 30-basis point lift. If I've got any part of that wrong, please say so. Are there additional refunds you've asked for, and where do those other requests stand right now? Turning to restructuring, I caught all the cost figures. I realize this is a project with a longer timeline — when do you think the savings from it will start showing up?

Karen Burton

executive
#25

Okay. Thanks, Jason. Yeah, regarding tariffs, you've got it right. During the quarter, we got $4 million. Roughly $27 million is the total we could potentially have available. Of that, 24 is claimable through the phase one and phase two claim processes; every one of those claims has been submitted by us. As far as what we're seeing, it's the first phase one refunds starting to arrive. When it comes to restructuring, that's essentially the expense of closing and combining the older facilities. All of those gains are factored into what we anticipate from the new facility — the advantages of consolidation and modernization.

Jason Bednar

analyst
#26

Alright, my apologies. I caught what was said before regarding adding capacity and upgrading facilities. Will this new plant bring about expense reductions or gains in efficiency, or does it lean more toward having no impact on costs?

Dan Carestio

executive
#27

At the outset, there won't be any cost impact, yet as time passes and we build scale within that operation, combining all that volume in a single site will allow us to extract substantially greater leverage. On top of that, we're putting in a lot of automation into the process, and that clearly raises the upfront expense, though the amount of labor needed to run this facility is dropping sharply.

Jason Bednar

analyst
#28

Understood. That's quite useful. I appreciate it.

Mike Polark

analyst
#29

Hello, good morning. A follow-up regarding AST services; for the remaining portion of the year, is it still reasonable to assume 7% to 8% organic for that segment? During the past several years, considerable growth CapEx went into AST to boost capacity. Are there launches scheduled for the remainder of the fiscal year that could potentially make growth stronger in 2H compared to what we'll witness in 1H? Thanks.

Dan Carestio

executive
#30

Thank you, Mike. Dan here. I'll take this one. Perhaps Karen would like to chime in. Regarding the modeling, indeed, we continue to completely anticipate AST will perform within the 7%- 8% range. Nothing has changed on that. As for the builds we're bringing online, the primary factor will be recovery from inventory destocking, returning to more typical volume moving through the facility. Those builds enable that, which is clearly incorporated into our figures as we comprehend it.

Karen Burton

executive
#31

As we bring those into service, the added depreciation is already accounted for in our models, and it's spread fairly evenly throughout the year. You'll notice depreciation increasing within that segment.

Mike Polark

analyst
#32

For my second question, the references to rising procedure volumes in endoscopies, a space where your exposure is significant, also caught my attention. What's behind that, in your view? Yeah, I'd like to hear your take on it. Thanks.

Dan Carestio

executive
#33

Over the past 2 years or so, there's been a shift being encouraged regarding the age at which detection happens early, and that's moved to under 50 years old now, so a greater number of individuals qualify or get brought in for endoscopies. My sense is that awareness of colon cancer is greater these days, and that may be generating some intake as a result. Yeah, listen, I can't stand here and claim it will hold up at the elevated level we're seeing at present, but endoscopy gave us a really robust quarter, and we observed the same among certain other peers operating in that same arena. Given what our service organization tells us, along with everything else, the growth we're witnessing there pleases us.

Mike Polark

analyst
#34

Thank you.

Dan Carestio

executive
#35

Yes, sir.

Mike Matson

analyst
#36

Yeah, thank you. I'd like to ask about the Nubis AI partnership that was made public in March. How do you see robotics and AI fitting into sterile processing? Might this partnership bring in significant revenue for STERIS?

Dan Carestio

executive
#37

Thank you, Mike. I appreciate that question. Right now it's at an early stage of development; we're quite enthusiastic about this technology. In my view, there will be a future in which some form of AI or robotic assistance plays a meaningful role in the SPD. As everyone knows, labor represents an enormous challenge in that setting, and certain tasks could eventually be automated over time, just as happens with any other process. We're putting in significant effort on something that remains fairly nascent at this point, and once we have more substantial information to share, we'll do so. For now, we're still in the early days.

Mike Matson

analyst
#38

Yeah, got it. So over in AST, capital came down once more. I realize that's only a small piece of that operation — first, could you walk us through what occurred? And second, would you remind us what kind of capital you sell within that unit? Thanks.

Dan Carestio

executive
#39

Sure, Mike — what we sell as capital is generally electron beam accelerators, and those go mainly to med tech customers, or into other uses involving electron beams; this business is lumpy since such projects might run anywhere from $2 million-$10 million for a single unit, sometimes higher. When we don't deliver a unit during a quarter, you get a massive swing compared with the earlier period if a unit does get delivered. As for total revenue from the equipment businesses, it moves around, roughly between $18 million and $30 million annually. This is entirely a matter of timing, and it's too small for us to really devote any time to.

Mike Matson

analyst
#40

Okay, thank you.

Dan Carestio

executive
#41

Yeah.

Julie Winter

executive
#42

I appreciate everyone setting aside part of your morning to be with us. I'm eager to reconnect with a lot of you outside this call, and in person while traveling this coming autumn.

Operator

operator
#43

That wraps up this conference. We appreciate your participation in today's presentation. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete STERIS plc transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to STERIS plc earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in STERIS plc or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.